Tilburg, C. M. v., Witt, R., Heiss, M., Pajtler, K. W., Plass, C., Poschke, I., . . . Witt, O. (2020). INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series : the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. BMC cancer, 20, . https://doi.org/10.1186/s12885-020-07008-8
Chicago-Zitierstil (17. Ausg.)Tilburg, Cornelis M. van, et al. "INFORM2 NivEnt: The First Trial of the INFORM2 Biomarker Driven Phase I/II Trial Series : The Combination of Nivolumab and Entinostat in Children and Adolescents with Refractory High-risk Malignancies." BMC Cancer 20 (2020). https://doi.org/10.1186/s12885-020-07008-8.
MLA-Zitierstil (9. Ausg.)Tilburg, Cornelis M. van, et al. "INFORM2 NivEnt: The First Trial of the INFORM2 Biomarker Driven Phase I/II Trial Series : The Combination of Nivolumab and Entinostat in Children and Adolescents with Refractory High-risk Malignancies." BMC Cancer, vol. 20, 2020, https://doi.org/10.1186/s12885-020-07008-8.